Should I switch cancer centers for my HER2-Low Breast Cancer treatment

Deciding Whether to Switch Cancer Centers for HER2-Low Breast Cancer

This is an important decision that deserves careful consideration. Let me help you think through this systematically by explaining what HER2-low breast cancer means, what treatment approaches exist, and key questions to ask your current team.

Understanding HER2-Low Breast Cancer

HER2-low breast cancer is more nuanced than the traditional HER2-positive/negative classification. According to the webinar "An MD PhD Navigates Breast Cancer" featuring Dr. [removed] Lopez-Correa (an MD/PhD who navigated her own breast cancer diagnosis), this complexity is important:

The "Gray Zone" of HER2 Status: Dr. [removed]-Correa explained that her tumor was initially reported as HER2-negative on standard pathology, but advanced sequencing detected a small HER2 amplification. She noted: "That also illustrates the complexity, which is not black and white. Are you positive? Are you negative? Like, I'm not positive, I'm not negative, I'm low."

This distinction matters because HER2-low tumors may respond to newer targeted therapies that weren't available just a few years ago.

Current Treatment Approaches for HER2-Low Breast Cancer

According to the webinar "Novel Therapies and New Directions in Pancreas Cancer, 2024" featuring Dr. [removed] O'Reilly, newer antibody-drug conjugates (ADCs) like Enhertu (trastuzumab deruxtecan) have recently been approved and represent a significant advancement. Dr. O'Reilly emphasized the importance of using the most current approved therapies rather than older treatment combinations.

Key treatment categories for HER2-low breast cancer include:

1. Antibody-Drug Conjugates (ADCs) - Newer drugs like Enhertu that deliver chemotherapy directly to HER2-expressing cells
2. Hormone therapy - If your tumor is also ER/PR positive
3. CDK4/6 inhibitors - Often combined with hormone therapy for aggressive tumors
4. Immunotherapy combinations - In select cases

When Switching Centers Makes Sense

Consider switching if:

• Your current center isn't offering the newest approved treatments for HER2-low breast cancer (like Enhertu or other recent ADCs)
• Your tumor has specific biomarkers that suggest targeted therapy options your current team hasn't discussed
• You want advanced molecular testing to guide treatment decisions
• Your current oncologist seems reluctant to discuss newer options or appears to be using older treatment protocols

When Staying May Be Appropriate

You might stay if:

• Your current team is knowledgeable about HER2-low disease and discussing current treatment options
• You have a good working relationship with your oncologist and they're responsive to your questions
• Your treatment is working well with manageable side effects
• Switching would cause significant disruption to your care continuity

Critical Questions to Ask Your Current Oncologist

Before making a decision, ask these specific questions:

1. "Given my HER2-low status, are you recommending Enhertu or other antibody-drug conjugates? If not, why?"

   • This is important because Enhertu has shown benefit in HER2-low breast cancer and is now FDA-approved for this indication.

2. "Have you reviewed my complete molecular profile (genomic testing)?"

   • According to Dr. [removed]-Correa's experience, advanced sequencing can reveal important mutations (like AKT1) that guide treatment decisions beyond standard pathology.

3. "What is my Ki-67 score, and how does it factor into your treatment recommendation?"

   • Dr. [removed]-Correa noted that Ki-67 (a measure of how fast cancer cells are dividing) was critical to her oncologist's decision to recommend CDK4/6 inhibitors. A high Ki-67 suggests more aggressive disease.

4. "Would you recommend any advanced testing like whole genome sequencing or multi-omic analysis?"

   • These tests can identify additional treatment targets beyond HER2.

5. "What is your experience treating HER2-low breast cancer specifically?"

   • This is a relatively newer classification, and not all oncologists may be equally familiar with the latest treatment approaches.

The Testing Question

The webinar "An MD PhD Navigates Breast Cancer" also highlighted an important consideration about testing. Dr. [removed]-Correa discussed whether to pursue circulating tumor DNA testing (like Signatera), noting that testing is most valuable when results will actually change treatment decisions. Ask your oncologist:

• "Would additional molecular testing change your treatment recommendations for me?"
• If the answer is "no," you might ask why not, or whether a second opinion might identify actionable findings.

How to Approach a Second Opinion

If you're considering switching:

1. **Request your complete [ID removed] - pathology report, imaging, lab results, genetic testing
2. Ask specifically about HER2-low treatment expertise when scheduling a consultation
3. Look for centers with active breast cancer research programs - they often have access to newer treatments
4. Consider academic medical centers - they tend to be earlier adopters of newly approved therapies

Red Flags That Suggest Switching

• Your oncologist dismisses newer treatments without explanation
• They seem unfamiliar with HER2-low breast cancer as a distinct entity
• They're unwilling to discuss or pursue molecular testing
• You feel rushed or unheard in appointments

Bottom Line

The decision to switch should be based on whether your current center can offer you the most current, evidence-based treatment options for HER2-low breast cancer. The field has evolved significantly in recent years, and newer targeted therapies like Enhertu represent real advances.

Start by having a detailed conversation with your current oncologist about the specific questions above. If they're knowledgeable, responsive, and discussing current treatment options, you may not need to switch. If they seem unfamiliar with HER2-low disease or resistant to newer approaches, a second opinion at a major cancer center would be very reasonable.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.